Wuhan Jinglong Biotech Debuts at North America’s Premier Pet Industry Expo — SUPERZOO in Las Vegas, USA; Its Pet Oral‑Dissolving‑Film Products Draw Attention from Overseas Buyers

Taking place from August 12‑14, 2026 (local time), SUPERZOO, one of North America’s most influential B2B pet‑industry trade shows, grandly opened at the Mandalay Bay Convention Center in Las Vegas, USA. Wuhan Jinglong Biotechnology Co., Ltd. showcased its series of pet oral dissolving‑film nutritional supplements at the expo. The company demonstrated China’s innovative R&D capabilities in pet‑product dosage‑form technology as well as its ODM/OEM manufacturing strengths to the North‑American market, while proactively expanding global overseas‑cooperation channels.

Hosted by the World Pet Association (WPA), SUPERZOO is a long‑standing and large‑scale premier B2B pet‑industry event across North America. This edition covered an exhibition area of over 30,000 square meters, gathering more than 1,200 exhibiting enterprises worldwide and attracting over 21,000 importers, brand owners, retail‑chain operators and procurement buyers from North America and across the globe. Centering on industry hot topics including pet nutrition & healthcare, innovative dosage forms and sustainable products, SUPERZOO serves as a core business‑matching platform for enterprises to access the North‑American pet market. A great variety of new products were unveiled on‑site, with functional pet‑nutritional supplements emerging as a highly sought‑after track. In particular, mucoadhesive fast‑absorption dosage forms captured heavy attention from overseas procurement buyers.

Jinglong Biotech operated two booths during this exhibition, displaying its full‑range core pet oral‑dissolving‑film nutritional supplements, including well‑developed formulations for joint care as well as calming & soothing effects. Diversified packaging solutions such as tin boxes and paper cartons were also on show. The company provides one‑stop complete OEM/ODM solutions for overseas clients, covering formula development, dosage‑form customization, manufacturing and packaging implementation. During the show, procurement buyers from multiple North‑American countries stopped by the booths to conduct in‑depth discussions regarding oral‑dissolving‑film technology, production qualifications, production‑capacity delivery and compliance certifications. Many merchants expressed initial intentions for business cooperation.

As a high‑tech Chinese contract‑manufacturing enterprise specializing in the R&D and production of pet oral dissolving films, Wuhan Jinglong Biotech runs cGMP‑compliant standardized workshops and fully‑automated oral‑dissolving‑film production lines. It holds multiple international certifications including HACCP, ISO22000 and FDA registration. The company also carries out industry‑university‑research collaborations with the Peking University School of Pharmaceutical Sciences, Tsinghua University School of Pharmaceutical Sciences, Institute of Materia Medica, Chinese Academy of Medical Sciences, and Lanzhou Institute of Animal Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences. Committed to technical upgrades of mucosal‑absorption fast‑dissolving dosage forms, its products meet market‑access standards for multiple countries worldwide.

Participation in SUPERZOO Las Vegas marks a key milestone for Jinglong Biotech in its deep‑rooted North‑American‑market strategy and accelerated global‑layout initiative. Leveraging top‑tier international professional‑expo platforms, the enterprise brings Chinese self‑developed innovative pet‑dosage‑form products to global markets. It actively engages with overseas brand owners and high‑quality channel partners to build long‑term two‑way‑cooperation frameworks, and keeps delivering high‑quality, professional OEM/ODM contract‑manufacturing services for pet nutritional supplements to clients across the world.

This Las‑Vegas‑based SUPERZOO is Jinglong Biotech’s second major overseas‑industry expo appearance this year, following its attendance at the Global Pet Expo in Orlando, USA, back in March. It fully demonstrates the firm’s strategic resolve to deepen its global‑market presence and steadily expand its overseas footprint. In parallel, Jinglong Biotech made a high‑profile appearance at China’s Shanghai Pet Fair Asia held August 19‑23, 2026. Industry partners from all sectors are warmly invited to visit its on‑site booth for product experience and business negotiations.

Company Profile

Located in Wuhan, Hubei Province, Wuhan Jinglong Biotechnology Co., Ltd. focuses on the R&D and large‑scale manufacturing of pet oral‑dissolving‑film mucosal‑absorption dosage‑form products. It provides OEM/ODM customization services for pet nutritional supplements to domestic and global clients. The enterprise owns its proprietary brand Hanxing, and also develops human‑targeted film‑candy product lines, with a complete system covering R&D, testing and mass production.